Diamond Therapeutics Announces First Patient Enrolled in FDA-authorized Study Evaluating Low-Dose Psilocybin in Human Subjects with Demoralization

The trial is being conducted at the University of Alabama at Birmingham (UAB) under noted psychedelic researcher Dr. Peter Hendricks This exploratory study is the first investigation of the influence of low-dose psilocybin on human subjects suffering from demoralization TORONTO, Oct. 17,…